Document Detail


Investigational drugs for neuroendocrine tumours.
MedLine Citation:
PMID:  19388877     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Neuroendocrine tumours (NETs) are usually slow-growing neoplasms, which arise in the gastrointestinal tract, endocrine pancreas, lungs or thymus. The majority are malignant. The treatment of patients with metastatic disease consists of biotherapy with alpha-interferon and somatostatin analogues, various chemotherapy combinations or liver embolization. OBJECTIVE: To review and discuss new treatments for patients with metastatic NETs. METHOD: Review of the published literature during the last 5 years on treatment of patients with NETs. RESULTS/CONCLUSION: Several new drugs with various mechanisms of action including cytotoxic drugs, tyrosine kinase receptor inhibitors and antiangiogenic drugs as well as radiolabelled substances have been introduced during recent years. Many of these compounds have shown promising results in patients with NETs.
Authors:
Dan Granberg
Related Documents :
21417557 - A comparison of drug use and risk behavior profiles among younger and older street youth.
3882257 - Stability of solutions of antineoplastic agents during preparation and storage for in v...
8637187 - Assessment of the cytotoxicity of the photosensitizing drug bpd verteporfin using human...
11783457 - Effects of common ophthalmic preservatives on ocular health.
8447677 - Telogen effluvium. new concepts and review.
10554047 - Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokine...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  18     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-24     Completed Date:  2010-01-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  601-8     Citation Subset:  IM    
Affiliation:
University Hospital, Institution of Medical Sciences, Department of Endocrine Oncology, Uppsala SE-75185, Sweden. dan.granberg@medsci.uu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / chemistry,  therapeutic use
Animals
Antineoplastic Agents / chemistry,  therapeutic use*
Drugs, Investigational / chemistry,  therapeutic use*
Humans
Neuroendocrine Tumors / drug therapy*,  metabolism
Protein Kinase Inhibitors / chemistry,  therapeutic use
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents; 0/Drugs, Investigational; 0/Protein Kinase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Next Document:  Recent developments in the treatment of uveitis: an update.